Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has received an average recommendation of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $110.1667.

Several research analysts recently commented on the company. TD Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Morgan Stanley increased their price target on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Evercore reaffirmed an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 20th. Finally, Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th.

Insider Activity

In other Mirum Pharmaceuticals news, Director Patrick J. Heron acquired 131,425 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were purchased at an average cost of $68.48 per share, for a total transaction of $8,999,984.00. Following the completion of the acquisition, the director owned 459,010 shares of the company’s stock, valued at approximately $31,433,004.80. The trade was a 40.12% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the sale, the chief executive officer owned 160,294 shares in the company, valued at $16,558,370.20. This represents a 5.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 45,136 shares of company stock worth $4,352,029. 14.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Cullen Frost Bankers Inc. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $32,000. CIBC Private Wealth Group LLC purchased a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $32,000. MCF Advisors LLC lifted its position in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth about $33,000.

Mirum Pharmaceuticals Trading Up 0.4%

MIRM stock opened at $105.49 on Friday. Mirum Pharmaceuticals has a 12-month low of $36.88 and a 12-month high of $107.41. The business’s 50-day moving average is $89.43 and its 200 day moving average is $77.22. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The stock has a market cap of $5.42 billion, a price-to-earnings ratio of -122.66 and a beta of 0.49.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.